Real-World Evidence Solutions Market to Reach $10.83 Billion by 2030, Driven by Shift to Value-Based Care and Accelerated Drug Development

The global real-world evidence (RWE) solutions market is projected to double from $5.42 billion in 2025 to $10.83 billion by 2030, representing a compound annual growth rate of 14.8%. This expansion is primarily fueled by a systemic shift toward value-based care and the pharmaceutical industry's urgent need for more efficient drug development processes. For the pharmaceutical sector, these solutions are becoming essential for generating actionable insights from patient data to improve clinical outcomes and streamline regulatory submissions.

The rapid growth of the RWE solutions market is underpinned by the increasing prevalence of chronic diseases and a surge in innovation across the pharmaceutical and medical device sectors. Healthcare stakeholders are turning to these solutions to process large-scale datasets, which facilitates faster and more cost-efficient drug development while enhancing decision-making across the ecosystem. The services segment, which includes advanced analytics and consulting, currently holds the largest market share as companies seek expertise in extracting meaningful insights from complex, real-world patient data to support clinical and regulatory goals.

Within the pharmaceutical industry, the drug development and approvals segment has emerged as the primary application for RWE solutions. Oncology is the leading therapeutic area in this space, driven by a global increase in cancer cases and a strategic focus on developing targeted therapies. By utilizing RWE to optimize clinical trial designs and provide evidence of treatment effectiveness in real-world settings, pharmaceutical companies can significantly reduce development timelines and mitigate the financial risks associated with potential drug recalls.

North America remains the dominant region for the RWE market, supported by a robust digital health infrastructure, widespread electronic health record adoption, and a favorable regulatory environment. Major industry players, including IQVIA, ICON Plc, Syneos Health, and Parexel, are actively expanding their AI-driven platforms and data partnerships to unlock the potential of real-world data. These organizations are helping pharmaceutical and biotechnology firms complement traditional clinical trial data with real-world outcomes, ultimately leading to the development of safer and more effective therapies.